GlassScriptPhysician profile
Andrew Tracey
NPI 1982014916
$13,241.73
in general payments reported to CMS, 2019-2025
44 companies · $2,780 in 2025
The $2,780 reported for 2025 was more than what 86% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $926 · 2020: $87.19 · 2021: $1,048 · 2022: $2,800 · 2023: $2,667 · 2024: $2,934 · 2025: $2,780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,304 · Education: $76.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,304.07 |
| Education | $76.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $1,492.73 | 2021-2025 | Provenge |
| Coloplast Corp | $1,320.72 | 2021-2025 | Titan |
| Sumitomo Pharma America, INC. | $952.79 | 2023-2025 | Gemtesa, Orgovyx |
| Olympus Corporation of The Americas | $879.77 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $770.31 | 2021-2025 | |
| Astellas Pharma US INC | $710.72 | 2021-2025 | Xtandi |
| Janssen Biotech, INC. | $639.10 | 2022-2025 | Erleada, Balversa, Akeega |
| Pfizer INC. | $580.79 | 2021-2025 | |
| Abbvie INC. | $532.82 | 2021-2025 | Botox, Lupron Depot |
| Urogen Pharma, INC. | $530.21 | 2021-2025 | Jelmyto |
| Karl Storz Endoscopy-America | $451.80 | 2022-2024 | Flex-X |
| Endo Pharmaceuticals INC. | $401.66 | 2021-2024 | Aveed, Xiaflex |
| Blue Earth Diagnostics | $375.85 | 2021-2024 | |
| Progenics Pharmaceuticals, INC. | $374.79 | 2022-2025 | Pylarify |
| Endo USA, INC. | $359.54 | 2024-2025 | Xiaflex, Aveed |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $312.94 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $287.65 | 2024-2025 | Adstiladrin |
| Amgen INC. | $228.27 | 2021-2023 | Prolia |
| Merck Sharp & Dohme LLC | $206.15 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Antares Pharma, INC. | $197.03 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Accord Healthcare, INC. | $173.34 | 2022-2025 | |
| Myovant Sciences INC. | $170.49 | 2021-2022 | |
| Immunitybio, INC. | $169.28 | 2024-2025 | |
| Boston Scientific Corporation | $160.02 | 2019-2023 | Rezum Generator |
| Astrazeneca Pharmaceuticals LP | $130.27 | 2021-2025 | Lynparza |
| Urovant Sciences INC | $129.50 | 2022 | |
| Sun Pharmaceutical Industries INC. | $108.33 | 2023-2024 | Yonsa |
| Tempus Ai, INC | $81.20 | 2024-2025 | Xt Cdx |
| Ambu INC. | $73.21 | 2023-2024 | |
| Cycle Pharmaceuticals INC | $64.49 | 2024-2025 | Tiopronin, Venxxiva |
| Ethicon US, LLC | $59.17 | 2022-2024 | Endopath Xcel, Stratafix, Echelon Flex |
| Cardinal Health 414 LLC | $49.08 | 2022-2025 | |
| Travere Therapeutics, INC. | $43.02 | 2021 | |
| Halozyme INC | $41.35 | 2023 | |
| Tolmar, INC. | $30.00 | 2024 | |
| Palette Life Sciences, INC. | $27.21 | 2022 | |
| Calyxo, INC. | $22.95 | 2024 | Cvac Aspiration System |
| Olympus America INC. | $18.83 | 2025 | Itind System |
| Foundation Medicine, INC. | $16.67 | 2022 | |
| Genzyme Corporation | $15.64 | 2022 | |
| Teleflex LLC | $13.87 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.06 | 2023 | Seglentis |
| Clarus Therapeutics INC. | $12.60 | 2021 | |
| Axonics, INC. | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Tracey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.